Savient on track to refile gout therapy Krystexxa in early 2010
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Savient Pharmaceuticals is well on its way to resolving issues raised in an FDA "complete response" letter for gout therapy Krystexxa (pegloticase) and plans to refile the BLA by early 2010 as planned, President Paul Hamelin said Sept. 16. Issues raised in the letter related to chemistry, manufacturing and controls; pre-approval inspection of the firm's third-party manufacturer; a safety update; proposed labeling; and the product's Risk Evaluation and Mitigation Strategy. It's a hefty list but all doable in time for the resubmission, the exec said, noting positive signals from FDA reviewers at a Sept. 14 meeting (1"The Pink Sheet" DAILY, Sept. 16, 2009)
You may also be interested in...
Savient On Track To Resubmit Krystexxa BLA In Early 2010, Exec Maintains
After a Sept. 14 meeting with the FDA, the biotech is confident it can satisfy all points in a complete response letter - including the gout therapy's REMS.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.